Publicaciones en colaboración con investigadores/as de Université de Toulouse (7)

2024

  1. 30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

    HemaSphere

  2. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Haematologica, Vol. 109, Núm. 7, pp. 2239-2249

2023

  1. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

2022

  1. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 416-427

2021

  1. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    Leukemia, Vol. 35, Núm. 1, pp. 31-44

2018

  1. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017